938443-19-7

Basic information

• Product Name: 7-Chloropyrido[2,3-d]pyrimidine-2,4-diol
• Synonyms: 7-Chloropyrido[2,3-d]pyrimidine-2,4-diol;7-chloropyrido[2,3-d]pyriMidine-2,4(1H,3H)-dione;7-Chloropyrido[2,3-d]pyriMidin-2,4(1H,3H)-dione;7-chloro-1H-pyrido[2,3-d]pyriMidine-2,4-dione;Pyrido[2,3-d]pyriMidine-2,4(1H,3H)-dione, 7-chloro-;7-ChloroPyrido[2,3-d]pyrimidine-2,4-dione;7-Chloropyrido[2,3-d]pyrimidine-2,4(1H,3H)
• CAS NO: 938443-19-7
• Molecular Formula: C₇H₄ClN₃O₂
• Molecular Weight: 197.581
• Mol File: 938443-19-7.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Density: 1.561±0.06 g/cm3 (20 ºC 760 Torr)
• Refractive Index: 1.608
• PKA: 9.06±0.20(Predicted)
• CAS DataBase Reference: 7-Chloropyrido[2,3-d]pyrimidine-2,4-diol(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Chloropyrido[2,3-d]pyrimidine-2,4-diol(938443-19-7)
• EPA Substance Registry System: 7-Chloropyrido[2,3-d]pyrimidine-2,4-diol(938443-19-7)

Safety Data

• Hazardous Substances Data: 938443-19-7(Hazardous Substances Data)

Usage

General Description

7-Chloropyrido[2,3-d]pyrimidine-2,4-diol, also known as CAS 853384-68-2, is a chemical compound with a molecular formula of C7H4ClN3O2. It belongs to the categories of pyridopyrimidines and halogenated heterocyclic compounds. This chemical is used in various fields and research areas due to its specific properties and structures. However, as of now, there isn't much detailed and specific information available about this chemical, its toxicity, or potential uses. Therefore, careful handling and usage are required for safety purposes.

InChI:InChI=1/C7H4ClN3O2/c8-4-2-1-3-5(9-4)10-7(13)11-6(3)12/h1-2H,(H2,9,10,11,12,13)

Upstream product

• 79-37-8 oxalyl dichloride 
• 64321-24-0 2-amino-6-chloro-pyridine-3-carboxamide 

Downstream Products

• 1424432-38-1 C₂₅H₃₁N₅O₃S 
• 1009303-44-9 (3S)-4-[7-chloro-2-[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d] pyrimidin-4-yl] 3-methyl-morpholine 
• 1424432-37-0 C₂₆H₃₄N₆O₂ 
• 1424432-36-9 C₂₅H₃₂N₆O₂ 
• 1424432-35-8 C₂₆H₃₄N₆O₃ 
• 938443-29-9 7-(3-chloromethyl-4-methoxy-phenyl)-2-((2S,6R)-2,6-dimethyl-morpholin-4-yl)-4-morpholin-4-yl-pyrido[2,3-d]pyrimidine 

Relevant articles and documents

Pyridopyrimidine KRAS G12C mutant protein inhibitor

The invention belongs to the technical field of medicines, and particularly relates to a pyridopyrimidine KRAS G12C mutant protein inhibitor shown in a general formula (I), pharmaceutically acceptable salts, stereoisomers and deuterated substances thereof. The invention also relates to a preparation method of the compounds, and a preparation method of the pharmaceutically acceptable salts, pharmaceutical preparations and pharmaceutical compositions containing the compounds. The invention also relates to the application of the compounds, pharmaceutically acceptable salts containing the compounds, pharmaceutical preparations and pharmaceutical compositions of the compounds in treatment of cancer proliferative diseases caused by KRAS G12C mutant protein.

PYRIDOPYRIMIDINE COMPOUNDS ACTING AS MTORC 1/2 DOUBLE-KINASE INHIBITORS

Disclosed are a series of pyridopyrimidine compounds and a use of same in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors, and specifically disclosed is a use of the compounds as shown in formula (IV), tautomers thereof or pharmaceutically acceptable salts thereof in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors.

Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014

The optimization of a potent and highly selective series of dual mTORC1 and mTORC2 inhibitors is described. An initial focus on improving cellular potency whilst maintaining or improving other key parameters, such as aqueous solubility and margins over hERG IC50, led to the discovery of the clinical candidate AZD8055 (14). Further optimization, particularly aimed at reducing the rate of metabolism in human hepatocyte incubations, resulted in the discovery of the clinical candidate AZD2014 (21).